"Innovation supply chain" could fill empty pipelines

06/27/2013 | Xconomy

Drugmakers have steadily reduced research and development budgets and turned to mergers, acquisitions, partnerships and, increasingly, their own venture capital funds to develop new drugs. But the strategy is lacking because it does not get drugmakers involved early enough in an innovation's development, writes Noubar Afeyan, founder, managing partner and CEO of Flagship Ventures. What is needed is an innovation supply chain that would force drugmakers to better define requirements and cultivate innovation development in the beginning stages, Afeyan writes.

View Full Article in:

Xconomy

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA